PSMA-PET引导的前列腺切除术后挽救放疗强化:2期随机临床试验
这项2期随机试验纳入130例根治性前列腺切除术后生化复发患者,随机接受标准挽救放疗或PSMA-PET/CT引导的强化挽救放疗。中位随访37个月,PSMA-PET引导强化组无失败生存显著改善(HR 0.50,95%CI 0.27-0.94,P=0.04),且毒性反应和生活质量无显著差异。
要点
- PSMA-PET引导强化挽救放疗改善无失败生存(HR 0.50,P=0.04)。
- 两组毒性和生活质量无显著差异,支持等毒性强化。
核心结论
- PSMA-PET引导的挽救放疗强化在根治性前列腺切除术后生化复发患者中实现等毒性的肿瘤控制改善。
研究设计与样本
- PSMAiSRT为PSMAgRT试验中的分层队列,是一项2期、两中心、基于注册的随机临床试验。
- 2018年5月至2021年2月共随机130例适合标准挽救放疗的根治性前列腺切除术后生化复发患者,其中2例未接受放疗。
- 患者1:1随机接受标准挽救放疗(前列腺床± elective盆腔放疗±辅助激素治疗)或PSMA-PET/CT引导的强化挽救放疗。
- 主要终点为无失败生存,定义为PSA进展(PSA最低值>0.2 ng/mL)、影像学进展、启动下一线治疗或死亡。
主要发现
- 128例患者中位(IQR)年龄71(64-74)岁,入组时中位(范围)PSA为0.3(0.1-3.0)ng/mL。
- PSMAiSRT组64例中33例(52%)接受强化挽救放疗,包括盆腔放疗16例(25%)、转移灶定向放疗2例(3%)、淋巴结推量19例(30%)或前列腺床推量15例。
- PSMAiSRT组下一线治疗事件较少(4 vs 12;HR 0.32;95%CI 0.11-1.02;P=0.04),两组毒性和生活质量无显著差异。
临床怎么用
- 对于根治性前列腺切除术后生化复发、适合挽救放疗的患者,可考虑PSMA-PET/CT引导的强化挽救放疗以改善无失败生存。
- PSA≥0.3 ng/mL的患者可能从PSMA-PET引导强化中获益更大。
- 强化策略未增加毒性或降低生活质量,支持其作为等毒性治疗选择。
局限性
- 本研究为2期试验,样本量有限,结论需等待后续3期试验的验证性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) offers superior accuracy in detecting prostate cancer lesions leading to intensified radiotherapy (RT), but its impact on patient outcomes is still undefined. OBJECTIVE: To evaluate whether intensification of salvage RT (SRT) after radical prostatectomy (RP) guided by PSMA-PET (PSMAiSRT) is associated with improved failure-free survival (FFS). DESIGN, SETTING, AND PARTICIPANTS: PSMAiSRT was a stratified cohort within a larger PSMA-guided intensification of radiotherapy (PSMAgRT) trial, a phase 2, two-center, registry-based randomized clinical trial. Patients with biochemical recurrence following RP who were eligible for standard-of-care (SOC) SRT from May 2018 to February 2021, were eligible for randomization in the PSMAiSRT stratum. A total of 130 patients were randomized, with 2 who did not proceed to radiotherapy (RT). The cutoff date for the primary analysis was October 26, 2023. INTERVENTION: Patients were randomized in a 1:1 ratio to receive either SOC SRT to the prostate bed, with or without elective pelvic RT, with or without adjuvant hormonal therapy (HT), or PSMA-PET/CT-guided SRT, intensified to detected sites of disease. MAIN OUTCOME AND MEASURES: The primary end point was FFS, defined as PSA progression (PSA nadir >0.2 ng/mL), radiological progression, next-line therapy initiation, or death. RESULTS: Among 128 patients (median [IQR] age, 71 [64-74] years), median (range) PSA at enrollment was 0.3 (0.1-3.0) ng/mL. In the PSMAiSRT group, 33 of 64 patients (52%) received intensified SRT; with addition of pelvic RT (n = 16 [25%]), metastasis-directed RT (n = 2 [3%]), lymph node boost (n = 19 [30%]), or prostate bed boost (n = 15). Adjuvant hormone therapy was equally prevalent in both arms (55 [86%] control vs 54 [84%] PSMAiSRT). At a median (range) follow-up of 37 (7-60) months, PSMAiSRT improved FFS (hazard ratio [HR], 0.50; 95% CI, 0.27-0.94; P = .04) and eugonadal FFS (HR, 0.45; 95% CI, 0.21-0.96; P = .03), with its greatest benefit in the subgroup with PSA of 0.3 ng/mL or more (HR, 0.17; 95% CI, 0.04-0.79; P = .01). Fewer next-line treatment events occurred in the PSMAiSRT arm (4 vs 12; HR, 0.32; 95% CI, 0.11-1.02; P = .04). There were no significant differences in toxic effects or quality of life between arms. CONCLUSION AND RELEVANCE: This phase 2 trial demonstrated an isotoxic improvement in cancer control with PSMA-PET-guided intensification of SRT after RP. Confirmatory evidence is awaited from a subsequently accrued phase 3 trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT03525288.
引用
- Belliveau C, Saad F, Duplan D, et al. Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 41037308. doi:10.1001/jamaoncol.2025.3746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。